8-K: AnaptysBio's Rosnilimab Achieves Positive Results in Phase 2b Rheumatoid Arthritis Trial, Showing Potential as a Novel Therapy

AnaptysBio announces positive top-line data from its Phase 2b RENOIR trial of rosnilimab in rheumatoid arthritis, demonstrating statistical significance on primary and key secondary endpoints.

Summary

• AnaptysBio announced positive top-line data from the Phase 2b RENOIR trial of rosnilimab for moderate-to-severe rheumatoid arthritis (RA).
• The trial, involving 424 patients, met its primary endpoint of mean change from baseline in DAS-28 CRP at Week 12 for all three doses of rosnilimab versus placebo.
• Rosnilimab also achieved statistical significance on key secondary endpoints like ACR20, ACR50, and CDAI LDA at Week 12.
• Notably, the study demonstrated the highest ever reported responses on key secondary endpoints at Week 14.
• 69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained responses out to Week 28.
• Rosnilimab demonstrated a favorable safety and tolerability profile, consistent with prior studies.
• Full Week 28 data and additional translational RA data are expected in Q2 2025.
• Top-line Week 12 Phase 2 ulcerative colitis data for rosnilimab are expected in Q4 2025.

Sentiment

Score: 8

Explanation: The document presents positive results from a Phase 2b trial, indicating potential for a new therapy in a large market. The favorable safety profile and strong efficacy data contribute to a positive outlook.

Positives

• The Phase 2b trial achieved its primary endpoint, demonstrating the efficacy of rosnilimab in treating RA.
• Rosnilimab showed statistically significant improvements in key secondary endpoints, indicating a broad impact on RA symptoms.
• The drug demonstrated a favorable safety and tolerability profile, suggesting it could be a safe option for long-term use.
• Rosnilimab appears to have a unique mechanism of action, potentially offering more durable relief of symptoms and disease modification.
• Translational blood biomarker data showed robust on-target pharmacological activity in rosnilimab-treated patients.
• 69% of patients achieved CDAI LDA at Week 14.

Negatives

• Higher than typical placebo rates were observed, which could potentially impact the interpretation of the results.
• The Week 28 data is still blinded and not yet available, so the sustainability of the observed benefits remains to be fully confirmed.
• Some patients discontinued treatment due to adverse events, although the overall rate was similar to placebo.

Risks

• The forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly.
• The company's ability to advance its product candidates, obtain regulatory approval, and commercialize its product candidates are subject to risks.
• The timing and results of preclinical and clinical trials are uncertain.
• The company's ability to fund development activities and achieve development goals is subject to risks.
• The company's ability to protect intellectual property is subject to risks.

Future Outlook

The company anticipates reporting full six-month data and additional translational data in Q2 2025, which they expect will further substantiate rosnilimab's impact on restoring healthy immune homeostasis in RA and additional diseases, such as ulcerative colitis. They also look forward to reporting top-line Week 12 Phase 2 data for rosnilimab in UC, now in Q4 2025.

Management Comments

• Daniel Faga, president and chief executive officer of Anaptys, stated that the findings surpass their target product profile in the ~$20 billion U.S. RA market.
• Jonathan Graf, M.D., professor of Medicine, Division of Rheumatology at the University of California, San Francisco and RENOIR investigator, is strongly encouraged by the Phase 2 data, which support the hypothesis that rosnilimab offers a fundamentally different approach to treating RA by resetting the immune system.
• Paul Emery, M.D., Versus Arthritis professor of rheumatology at the University of Leeds and Leeds Biomedical Research Centre, UK, stated that rosnilimab's efficacy data paired with a favorable safety and tolerability profile present a promising new option for people living with RA.
• Paul Lizzul, M.D., Ph.D., chief medical officer of Anaptys, stated that the positive clinical and translational data validate their scientific approach to target the PD-1 co-inhibitory receptor on activated immune cells in RA, as well as other heterogeneous, systemic autoimmune and inflammatory diseases, including UC.

Industry Context

The announcement highlights the potential for rosnilimab to address the unmet need for innovative therapies in the RA market, where no new drug classes have been approved in the last decade. The drug's differentiated mechanism of action, targeting PD-1+ T cells, could offer a new approach to treating RA and other inflammatory diseases.

Comparison to Industry Standards

• The document compares Rosnilimab Week 14 efficacy to all-active head-to-head comparator studies at Week 24, showing Rosnilimab surpassing competitors.
• Competitors mentioned include Rinvoq, Orencia, and Kevzara.
• The document also mentions that black box warnings for increasing SAE incidence of commercial products have not impeded blockbuster sales.
• The document compares infection rates, MACE rates, and malignancy rates of commercial products to Rosnilimab's safety profile.

Stakeholder Impact

• The positive results could benefit shareholders through increased stock value.
• Patients with rheumatoid arthritis could benefit from a new and effective treatment option.
• The company's employees could benefit from the success of the clinical trial and potential commercialization of rosnilimab.

Next Steps

• The company will report full Phase 2b Week 28 data in Q2 2025.
• Additional translational data will be reported in Q2 2025.
• The company will present the data at a medical conference.
• Top-line Phase 2 data for ulcerative colitis is expected in Q4 2025.
• Initiation of ANB101's Phase 1 clinical trial is planned for Q1 2025.

Key Dates

Keywords

rosnilimab, rheumatoid arthritis, RA, clinical trial, Phase 2b, AnaptysBio, immunology, PD-1, autoimmune, inflammation